Sugi Predict

Sugi Predict / Compounds / SCHEMBL5693269

SCHEMBL5693269

SCHEMBL5693269

CC1=NN(c2ccccc2)C(c2ccc(S(C)(=O)=O)cc2)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.59
▸ ALDH1A1 P00352 6/20 0.59
▸ HTT P42858 2/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ PTGS2 P35354 11/20 0.58
▸ PTGS1 P23219 2/20 0.52
▸ CA1 P00915 2/20 0.49
▸ CA2 P00918 2/20 0.49
▸ KDM4E B2RXH2 4/20 0.48
▸ GLA P06280 4/20 0.48
▸ GAA P10253 4/20 0.48
▸ ATM Q13315 3/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ CFTR P13569 1/20 0.48
▸ GOPC Q9HD26 1/20 0.48
▸ PDE5A O76074 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5693258 0.89 PTGS2 (0.53) MAPTALDH1A1HTTSMN1; SMN2PTGS2
SCHEMBL5693257 0.86 PTGS2 (0.66) MAPTALDH1A1HTTSMN1; SMN2PTGS2
SCHEMBL28576620 0.84 PTGS2 (0.76) MAPTALDH1A1HTTPTGS2CA1
SCHEMBL8103392 0.83 MAPT (0.68) MAPTALDH1A1HTTSMN1; SMN2CA1
SCHEMBL27493301 0.83 PTGS2 (0.51) MAPTALDH1A1HTTSMN1; SMN2PTGS2
SCHEMBL5693225 0.83 PTGS2 (0.55) MAPTALDH1A1HTTSMN1; SMN2PTGS2
SCHEMBL5693232 0.82 PTGS2 (0.76) MAPTALDH1A1PTGS2PTGS1PDE5A
SCHEMBL5856383 0.77 CA1 (0.67) MAPTALDH1A1HTTPTGS2CA1
SCHEMBL27575517 0.77 MAPT (0.56) MAPTALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL5693406 0.76 PTGS2 (0.76) MAPTALDH1A1HTTPTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1299682-C Use of pyrazoline derivatives for the preparation of a medicament for the prevention and/or treatment of cell proliferative diseases DEL DR ELSTEVE S A LAB (ES) 2007-02-14 — — CN claimed
EP-1384477-B1 UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES ESTEVE LABOR DR (ES) 2006-05-24 — — EP claimed
CN-1509171-A Use of pyrazoline derivatives for the preparation of a medicament for the prevention and/or treatment of cell proliferative diseases ��˹���IJ�ʿʵ���ҹɷ����޹�˾ 2004-06-30 — — CN claimed
US-20040034082-A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2004-02-19 — — US claimed
EP-1384477-A1 UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2004-01-28 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034082-A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases VHL, MET, PRMT1 MAPT 4760/4885ALDH1A1 2430/4885HTT 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.